Accelerating the integration of China into the global development of innovative anticancer drugs

The aim of this Policy Review was to compare China's overall and synchronous participation in clinical trials for innovative anticancer drugs with that of the USA, the EU, Japan, and South Korea, and to assess changes in the participation rate trends in these five regions. Relevant data from th...

Full description

Saved in:
Bibliographic Details
Published in:The lancet oncology 2022-11, Vol.23 (11), p.e515-e520
Main Authors: Huang, Huiyao, Wu, Dawei, Miao, Huilei, Tang, Yu, Liu, Chengcheng, Fang, Hong, Meng, Xinyu, Wang, Shuhang, Zhu, Qi, Wang, Xin, Du, Jingting, Yang, Zhimin, Li, Ning, Xu, Binghe, He, Jie
Format: Article
Language:English
Subjects:
Antineoplastic drugs
Antitumor agents
Cancer
Clinical trials
Developmental stages
Drug development
Participation
Pharmaceutical industry
Prescription drugs
R&D
Research & development
Statistical analysis
Trends
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this Policy Review was to compare China's overall and synchronous participation in clinical trials for innovative anticancer drugs with that of the USA, the EU, Japan, and South Korea, and to assess changes in the participation rate trends in these five regions. Relevant data from the top 20 international pharmaceutical companies from 2011 to 2021 were systematically collected from the Trialtrove and Pharmaprojects databases. Among the 8260 trials for 954 new anticancer drugs identified, China was involved in 8·8% of the trials and with 20·4% of the drugs being trialled. These participation rates are significantly lower than those for South Korea (14·5% of trials and 36·3% of drugs), Japan (16·1% of trials and 38·7% of drugs), the EU (40·6% of trials and 67·7% of drugs), and the USA (65·7% of trials and 91·2% of drugs; p
ISSN:1470-2045
1474-5488
DOI:10.1016/S1470-2045(22)00483-1